Which medication would be considered a first-line medication therapy for generalized anxiety disorder (GAD)?

Choice A reason: Predicting individual recovery is not epidemiology’s role. Recovery from disorders like depression depends on neurobiological factors (e.g., serotonin reuptake) and treatment adherence, not population-level trends. Epidemiology focuses on group patterns, not individual outcomes, making this option scientifically inaccurate for understanding mental disorder impact.

Choice B reason: Epidemiology does not provide theoretical explanations for disorder causes. Etiologies of mental illnesses, such as genetic mutations or dopamine imbalances in schizophrenia, are studied through neurobiology and genetics. Epidemiology quantifies disease prevalence and risk factors, not underlying mechanisms, making this option misaligned with its scientific purpose.

Choice C reason: Explaining neurophysiological causes is outside epidemiology’s scope. Neurophysiology, like altered GABA activity in anxiety, is studied via neuroimaging or biochemical assays. Epidemiology identifies disease patterns and risk factors across populations, not causal mechanisms, rendering this option incorrect for describing its role in mental health.

Choice D reason: Epidemiology studies disease distribution and determinants, such as prevalence of depression or risk factors like socioeconomic stress, which influence neurotransmitter imbalances (e.g., serotonin). By analyzing population data, it informs public health strategies, identifies at-risk groups, and guides interventions, making it critical for understanding mental disorder impact scientifically.

Choice A reason: Paroxetine, an SSRI, is first-line for GAD, enhancing serotonin in the amygdala and prefrontal cortex, reducing excessive worry. Its efficacy and tolerability, with minimal dependence risk, align with evidence-based guidelines for long-term anxiety management, making it the preferred choice.

Choice B reason: Imipramine, a tricyclic antidepressant, affects serotonin and norepinephrine but has significant anticholinergic side effects, reducing tolerability. It is not first-line for GAD due to slower onset and side effect profile compared to SSRIs, which better target anxiety’s neurobiological basis.

Choice C reason: Hydroxyzine, an antihistamine, reduces anxiety via histamine receptor blockade, causing sedation. It is used as needed, not for chronic GAD management. SSRIs, like paroxetine, offer sustained serotonin modulation, making hydroxyzine a less effective, non-first-line option for long-term treatment.

Choice D reason: Alprazolam, a benzodiazepine, enhances GABA activity, providing rapid anxiety relief but carries high dependence risk. It is not first-line for GAD, as SSRIs offer safer, long-term serotonin-based treatment, making alprazolam unsuitable for chronic management due to addiction potential.